Julie Huynh-Lu, PA
Physician Assistant · Houston, TXNPI 1770992877
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 62.5% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $18,419, 5.8 times the $3,180 reported in 2021. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $228.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$40K
- GSK$16K
- Blueprint Medicines Corporation$3K
- E.r. Squibb & Sons, L.L.C.$1K
- AbbVie$844
- AstraZeneca$648
- plus $3K from 21 others
What the payments were for
- Consulting fees$14,12822%
- Speaking & faculty fees$28,08044%
- Grants$5001%
- Travel & lodging$12,96920%
- Food & beverage$8,21913%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 108 | $40,085 |
| GSK | 28 | $15,502 |
| Blueprint Medicines Corporation | 9 | $2,979 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,260 |
| AbbVie | 13 | $844 |
| AstraZeneca | 20 | $648 |
| Astellas Pharma US Inc | 16 | $465 |
| Bristol Myers Squibb | 17 | $326 |
| Lilly USA, LLC | 9 | $284 |
| Pharmaessentia USA Corporation | 10 | $252 |
| Pfizer | 4 | $227 |
| Sobi, Inc | 7 | $199 |
| Novartis | 6 | $164 |
| Johnson & Johnson | 6 | $142 |
| W. L. Gore & Associates, Inc. | 1 | $126 |
| Merck | 4 | $103 |
| Rigel Pharmaceuticals, Inc. | 3 | $90 |
| Amgen | 3 | $81 |
| Beigene USA, Inc. | 2 | $55 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Taiho Oncology, Inc. | 2 | $52 |
| Adaptive Biotechnologies Corporation | 2 | $38 |
| Syndax Pharmaceuticals, Inc. | 1 | $32 |
| CTI Biopharma Corp. | 1 | $25 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Invivyd Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,096 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 125 | $2,161,480 |
| OjjaaraMomelotinib Dihydrochloride | 53 | $1,435,444 |
| TasignaNilotinib Hcl | 31 | $392,018 |
| VonjoPacritinib Citrate | 12 | $316,785 |
| SprycelDasatinib | 32 | $218,952 |
| CalquenceAcalabrutinib Maleate | 14 | $217,114 |
| BosulifBosutinib | 14 | $188,370 |
| BrukinsaZanubrutinib | 13 | $164,653 |
| ImbruvicaIbrutinib | 14 | $150,057 |
| VenclextaVenetoclax | 19 | $126,257 |
| Imatinib Mesylate | 25 | $65,310 |
| Posaconazole | 12 | $7,500 |
| ValacyclovirValacyclovir Hcl | 92 | $2,401 |
| Prochlorperazine Maleate | 13 | $359 |
| Hydroxyurea | 18 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $40,085 | $2,161,480125 claims |
| GSKOjjaara | $15,502 | $1,435,44453 claims |
| NovartisTasigna | $164 | $392,01831 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $1,260 | $218,95232 claims |
| AstraZenecaCalquence | $648 | $217,11414 claims |
| PfizerBosulif | $227 | $188,37014 claims |
| Beigene USA, Inc.Brukinsa | $55 | $164,65313 claims |
| AbbVieVenclexta | $844 | $126,25719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Houston
- Simone SteeleHouston$237K
- Amanda WilhiteHouston$207K
- Christina YazdaniHouston$72K
- Jennifer FalconeHouston$48K
- Jacqueline WeatherlyHouston$47K
- Samantha SalvatoraHouston$45K
- Virginia SchneiderHouston$43K
- Jill MillerHouston$32K
- Mercedes SerranoHouston$28K
- Cynthia TrickettDallas$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.